Loading stock data…
$5.73+0.17 (+3.06%)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Valneva SE in the Healthcare sector is trading at $5.73 with a market capitalization of $540M. Wall Street consensus targets $12.25 (4 analysts), implying a +113.8% move over the next 12 months. The stock is currently near its 52-week low of $4.75, remaining 18.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $34.94M↑ | $30.90M↓ | $47.69M↑ | $29.41M↓ | $48.33M |
| Gross Profit | $1.60M↓ | $4.72M↓ | $11.62M↑ | $5.50M↓ | $24.21M |
| Operating Income | -$26.17M↓ | -$23.70M↑ | -$27.68M↑ | -$37.35M↓ | -$10.64M |
| Net Income | -$31.20M↑ | -$32.07M↑ | -$50.02M↓ | -$44.35M↓ | -$11.59M |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for...